Pretreating With P2Y12 Inhibitors in STEMI Does It Make Any Difference?

被引：0
|
作者：
Stouffer, George A. [1 ,2 ]
Friede, Kevin A. [1 ,2 ]
Rossi, Joseph S. [1 ]
机构：
[1] Univ N Carolina, Div Cardiol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, McAllister Heart Inst, Chapel Hill, NC 27599 USA
来源：
JACC-CARDIOVASCULAR INTERVENTIONS | 2024年 / 17卷 / 01期
关键词：
antiplatelet therapy; myocardial infarction; STEMI;
D O I：
10.1016/j.jcin.2023.11.017
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 31
页数：3
相关论文
共 50 条
  • [21] Thrombus remodelling by reversible and irreversible P2Y12 inhibitors
    Tunstromer, Kjersti
    Faxalv, Lars
    Larsson, Pia
    Lindahl, Tomas L.
    Boknas, Niklas
    PLATELETS, 2023, 34 (01)
  • [22] Republished Education in Heart: New P2Y12 inhibitors
    Storey, Robert F.
    POSTGRADUATE MEDICAL JOURNAL, 2012, 88 (1035) : 49 - 54
  • [23] Elderly patients are hyperresponsive to potent P2Y12 inhibitors
    Mutschlechner, D.
    Tscharre, M.
    Wadowski, P.
    Lee, S.
    Pultar, J.
    Weikert, C.
    Panzer, S.
    Gremmel, T.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [24] Trends in Spending for P2Y12 Inhibitors by Medicare and Medicaid
    Essa, Mohammed
    Ross, Joseph S.
    Dhruva, Sanket
    Desai, Nihar R.
    Yeh, Robert W.
    Faridi, Kamil
    CIRCULATION, 2022, 146
  • [25] P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
    Scott, Day Marice
    Norwood, Rhonda M.
    Parra, David
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (01) : 64 - 76
  • [26] P2Y12 inhibitors: do they increase cancer risk?
    Fierro, Joseph J.
    Cave, Brandon
    Khouzam, Rami N.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (17)
  • [27] New P2Y12 inhibitors versus clopidogrel in primary percutaneous coronary intervention for STEMI: a meta-analysis
    Bellemain, A.
    Brieger, D.
    Beygui, F.
    Silvain, J.
    Cayla, G.
    Barthelemy, O.
    Collet, J. -P.
    Montalescot, G.
    EUROPEAN HEART JOURNAL, 2011, 32 : 421 - 421
  • [28] P2Y12 Inhibitors in Chronic Coronary Syndromes Undergoing Elective PCI Any Niche for Potent Agents?
    Ferreiro, Jose Luis
    JACC-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (03) : 371 - 373
  • [29] Antiplatelet therapy: Third-generation P2Y12 inhibitors - A new gold standard for PCI after STEMI?
    Osório J.
    Nature Reviews Cardiology, 2010, 7 (11) : 599 - 599
  • [30] Antiplatelet Therapy n ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors
    Ristorto, Jessica
    Messas, Nathan
    Marchandot, Benjamin
    Kibler, Marion
    Hess, Sebastien
    Meyer, Nicolas
    Schaeffer, Michael
    Tuzin, Nicolas
    Ohlmann, Patrick
    Jesel, Laurence
    Morel, Olivier
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (08) : 674 - 689
12345